{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:25:00Z","timestamp":1780611900825,"version":"3.54.1"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T00:00:00Z","timestamp":1346976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>To investigate the differences of <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> lymphocyte stimulator (<jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>) level and frequency of lymphocytes between sero\u2010negative and sero\u2010positive rheumatoid arthritis (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Sixty\u2010nine <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients were enrolled into this study and their clinical data were recorded. The <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> levels in plasma, frequency of <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> lymphocytes, as well as <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>\u2010helper (<jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>h) subgroups were compared between sero\u2010negative and sero\u2010positive <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients. Furthermore, the correlations between clinical features and immunological features were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The plasma <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> level in sero\u2010negative <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> was higher compared to the sero\u2010positive <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients (1.73\u00a0\u00b1\u00a01.71 <jats:italic>vs<\/jats:italic>. 0.99\u00a0\u00b1\u00a00.59\u00a0ng\/mL, <jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05) and osteoarthritis (<jats:styled-content style=\"fixed-case\">OA<\/jats:styled-content>) patients (1.73\u00a0\u00b1\u00a01.71 <jats:italic>vs<\/jats:italic>. 0.59\u00a0\u00b1\u00a00.12\u00a0ng\/mL, <jats:italic>P\u00a0<\/jats:italic>&lt;<jats:italic>\u00a0<\/jats:italic>0.05). Plasma <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> level was correlated with disease activity score (<jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content>\u201028, erythrocyte sedimentation rate and <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>\u2010reactive protein), but had no correlation with the titers of rheumatoid factor and anti\u2010cyclic citrullinated peptide (anti\u2010<jats:styled-content style=\"fixed-case\">CCP<\/jats:styled-content>) antibodies. The patients with more advanced changes in <jats:styled-content style=\"fixed-case\">X<\/jats:styled-content>\u2010rays had high plasma <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> levels. No significant differences in the frequency of <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content> lymphocytes, <jats:styled-content style=\"fixed-case\">T<\/jats:styled-content>h subpopulations and <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content> lymphocytes in peripheral blood were observed between sero\u2010negative and sero\u2010positive <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Plasma <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> level was correlated with disease activity and radiological progress, which indicates that plasma <jats:styled-content style=\"fixed-case\">B<\/jats:styled-content>ly<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content> level may become a useful biological marker to reflect <jats:styled-content style=\"fixed-case\">DAS<\/jats:styled-content> and to predict <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> prognosis.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1756-185x.2012.01814.x","type":"journal-article","created":{"date-parts":[[2012,9,7]],"date-time":"2012-09-07T12:50:25Z","timestamp":1347022225000},"page":"478-485","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative study on the level of <scp>B<\/scp> lymphocyte stimulator (<scp>B<\/scp>ly<scp>S<\/scp>) and frequency of lymphocytes between sero\u2010negative and sero\u2010positive rheumatoid arthritis patients"],"prefix":"10.1111","volume":"15","author":[{"given":"Yan","family":"Geng","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Beijing University First Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo\u2010li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology Beijing University First Hospital Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.50.5.275"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2007.02.004"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1313.004"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000082106"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.025502"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10860"},{"key":"e_1_2_7_10_1","first-page":"1256","article-title":"Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis","volume":"35","author":"Bosello S","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2773"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.190.11.1697"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.97.7.3370"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1061964"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00183-2"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00130-3"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/89790"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21650"},{"key":"e_1_2_7_19_1","first-page":"449","article-title":"Interleukin\u20101 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL\u20101 alpha","volume":"73","author":"Buchan G","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401203"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013680"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/39.5.513"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2007.04.005"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5703"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2477"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0806044105"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2012.01814.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2012.01814.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T19:27:11Z","timestamp":1698780431000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2012.01814.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,7]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1756-185X.2012.01814.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2012.01814.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,7]]},"assertion":[{"value":"2012-09-07","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}